Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial
Chimeric Therapeutics (ASX:CHM) has reported one leukaemia patient has shown a complete response in its latest drug trial.
B2Y
0.00%
2.9¢
BOUNTY MINING LIMITED
Currently unlisted.
Proposed listing date: TUESDAY 19 JUNE 2018, 11:00 AM AEST ##
Add to my watchlist
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
B2Y | Ann: Removal from Official List | 01/02/21 | 0 | 611 | |||
|
|||||||
B2Y | News: B2Y ASX Says Bounty Mining Will Be Removed From Official List At Close Of Trading On Feb 1 | 01/02/21 | 0 | 359 | |||
|
|||||||
B2Y | Ann: Failure to pay annual listing fees | 24/08/20 | 0 | 793 | |||
|
|||||||
B2Y | Ann: Expressions of Interest | 17/08/20 | 6 | 9.3K | |||
|
|||||||
B2Y | Ann: Completion of sale | 03/07/20 | 1 | 1.5K | |||
|
|||||||
B2Y | Ann: Notice of Financial Reporting Relief | 22/06/20 | 0 | 619 | |||
|
|||||||
B2Y | News: B2Y Pwc Updates On Recapitalization Process For Bounty Mining | 30/03/20 | 0 | 510 | |||
|
|||||||
B2Y | Ann: Update on Recapitalisation | 30/03/20 | 0 | 750 | |||
|
See All Discussions